Trial Profile
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care (SOC) Compared to Placebo With SOC in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2022
Price :
$35
*
At a glance
- Drugs Pomaglumetad methionil (Primary) ; Aripiprazole; Olanzapine; Quetiapine; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Denovo Biopharma
- 29 Aug 2012 Primary endpoint 'Assessment-scale-scores' has not been met, according to an Eli Lilly media release.
- 20 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.